Drugs Containing Excipient (Inactive Ingredient) NONOXYNOL-9

« Back to Dashboard

Branded drugs containing NONOXYNOL-9 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	BETADINE	povidone-iodine	0065-0411	NONOXYNOL-9
Rebel Distributors Corp	BETADINE	povidone-iodine	42254-006	NONOXYNOL-9

Generic drugs containing NONOXYNOL-9 excipient

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	povidone-iodine	0065-0411	NONOXYNOL-9
Rebel Distributors Corp	povidone-iodine	42254-006	NONOXYNOL-9

Nonoxynol-9 Market Dynamics, Regulatory Status, Patent Position, and Financial Trajectory

Last updated: October 6, 2026

Nonoxynol-9 is a nonionic surfactant used primarily as a vaginal spermicide and, in smaller volumes, as a pharmaceutical excipient, laboratory reagent, and formulation aid. Its commercial trajectory is mature to declining in contraception, with demand concentrated in low-cost over-the-counter products and selected institutional markets. Public companies do not generally report nonoxynol-9 revenue separately, so precise market size and supplier-level financial forecasts are unavailable from audited disclosures.

What is nonoxynol-9 and how is it used in pharmaceutical products?

Nonoxynol-9 is a polyethylene glycol ether of nonylphenol. It is commonly identified by the INCI name nonoxynol-9 and by chemical names such as nonylphenol ethoxylate containing approximately nine ethylene oxide units.

Its principal pharmaceutical function is spermicidal activity. The compound disrupts sperm-cell membranes and reduces sperm motility. Products historically containing nonoxynol-9 include:

• Vaginal contraceptive gels
• Foams
• Creams
• Films
• Suppositories
• Tablets
• Condom and diaphragm formulations
• Certain topical or laboratory formulations requiring a nonionic surfactant

The commercial distinction between nonoxynol-9 as an active ingredient and as an excipient is important. In vaginal contraceptive products, it is the active spermicidal ingredient. In other formulations, it may act as a surfactant, emulsifier, wetting agent, solubilizer, or dispersion aid.

Attribute	Nonoxynol-9
Chemical class	Nonionic surfactant
Primary pharmaceutical role	Vaginal spermicide
Secondary role	Surfactant and formulation aid
Molecular profile	Ethoxylated nonylphenol mixture
Principal dosage forms	Gel, foam, film, cream, tablet, suppository
Main regulatory concern	Local irritation and mucosal toxicity
Main commercial substitutes	Other surfactants, polysorbates, poloxamers, alkyl glucosides
Market maturity	Mature, with declining contraceptive demand in developed markets
Public revenue disclosure	Generally unavailable on a standalone basis

What is the current market size for nonoxynol-9?

No authoritative public source provides a consolidated global revenue figure for pharmaceutical-grade nonoxynol-9. Published market-research estimates often combine industrial nonylphenol ethoxylates, personal-care surfactants, spermicides, and pharmaceutical excipients. Those categories are not interchangeable.

The addressable pharmaceutical market is small compared with the broader nonionic-surfactant market. Pharmaceutical demand is divided into three segments:

1. Finished spermicide products
2. Contract-manufactured vaginal contraceptive products
3. Excipient and formulation applications

Spermicide is the largest identifiable pharmaceutical use, but it has limited growth potential. In the United States, nonoxynol-9 products remain available as nonprescription vaginal contraceptives, but they compete against condoms, oral contraceptives, intrauterine devices, implants, emergency contraception, and prescription vaginal products.

The excipient segment has more stable technical demand but lower volume. Manufacturers may select nonoxynol-9 for wetting or emulsification, yet regulatory and toxicological concerns limit its use in products applied to mucosal tissue or damaged skin.

Why standalone financial data is limited

Nonoxynol-9 is usually purchased as a commodity or specialty chemical rather than as a separately reported pharmaceutical franchise. Suppliers may sell it within broader portfolios of:

• Nonionic surfactants
• Ethoxylates
• Pharmaceutical excipients
• Personal-care ingredients
• Industrial detergents
• Laboratory reagents

Large chemical companies generally report results by geographic region or business segment. They do not identify nonoxynol-9 revenue, gross margin, volume, or customer concentration. Finished-product marketers also tend to disclose contraceptive revenue at the brand or category level rather than by active ingredient.

Consequently, any precise estimate of global nonoxynol-9 revenue should be treated as a modeled figure rather than audited market data.

What market forces are affecting nonoxynol-9 demand?

The market is shaped by declining use of spermicides, low manufacturing complexity, regulatory scrutiny, and substitution by newer contraceptive technologies.

Declining use of spermicide as a primary contraceptive

Nonoxynol-9 has limited effectiveness when used alone. The Centers for Disease Control and Prevention identifies typical-use failure rates for spermicide as materially higher than those for long-acting reversible contraceptives and hormonal methods (CDC, 2024).

Spermicide remains relevant where users need:

• Nonhormonal contraception
• User-controlled, on-demand contraception
• A low-cost product
• Compatibility with condoms or diaphragms
• Access without a prescription

Its use is constrained by the need for repeated application and by local irritation. These factors make it less attractive than long-acting methods and daily or weekly contraceptive options.

Safety concerns affecting repeat use

Frequent use of nonoxynol-9 can irritate vaginal and rectal mucosa. The World Health Organization and UNAIDS have concluded that nonoxynol-9 does not prevent HIV or other sexually transmitted infections and can increase the risk of HIV transmission when used frequently by individuals at high risk of HIV exposure (WHO & UNAIDS, 2002).

The safety profile affects both demand and product positioning. Labels commonly state that nonoxynol-9 should not be used for protection against HIV or sexually transmitted infections. This limits its use in public-health programs focused on dual protection.

Competition from alternative surfactants

In excipient applications, formulators can evaluate:

• Polysorbate 20 and polysorbate 80
• Poloxamer 188 and poloxamer 407
• Sorbitan esters
• Alkyl polyglucosides
• Lecithin-based systems
• PEG-based surfactants
• Silicone and fluorinated surfactants for specialized uses

These alternatives may offer better toxicological acceptance, broader compendial familiarity, lower odor, improved batch consistency, or better regulatory support. Nonoxynol-9 retains advantages in cost, availability, and established technical performance, but those advantages are weaker in new drug development.

What is the FDA regulatory status of nonoxynol-9?

Nonoxynol-9 is recognized in the United States as an active ingredient for over-the-counter vaginal contraceptive products under the FDA’s nonprescription drug framework. FDA regulations historically identified nonoxynol-9 among active ingredients eligible for spermicide products when used at permitted concentrations and with required labeling.

The FDA regulatory position is product-specific. A manufacturer must comply with the applicable OTC monograph or obtain an approved application, use permitted labeling, and meet finished-product quality requirements. The presence of nonoxynol-9 in a formulation does not independently establish market authorization.

Relevant regulatory issues include:

• Active-ingredient concentration
• Dosage form
• Applicator design
• Microbiological quality
• Stability
• Local irritation
• Required contraceptive warnings
• Claims relating to sexually transmitted infections
• Manufacturing under current good manufacturing practice

The FDA’s labeling position is commercially material. Nonoxynol-9 products cannot be positioned as protection against HIV or sexually transmitted infections. That limitation removes a major potential market in infection prevention (FDA, 2023; CDC, 2024).

European and international regulatory considerations

Regulatory treatment varies by jurisdiction. In the European Union, the applicable legal pathway depends on whether the product is classified as a medicinal product, medical device, cosmetic, or chemical ingredient. Vaginal contraceptive products may face requirements involving medicinal-product authorization, medical-device rules, or national classification.

In many markets, nonoxynol-9 is accepted for contraceptive use but remains subject to restrictions on claims and warnings. Exporters must also address:

• Pharmacopoeial or customer specifications
• REACH obligations for chemical substances
• Local chemical-registration requirements
• Residual ethylene oxide and 1,4-dioxane limits
• Microbial limits
• Heavy metals and elemental impurities
• Packaging compatibility

What formulations are protected by nonoxynol-9 patents?

Nonoxynol-9 itself is an old chemical entity and is not protected by a meaningful composition-of-matter patent estate. Any original patent protection for the active compound would have expired decades ago.

Potentially relevant rights may cover:

• Specific spermicide formulations
• Vaginal films
• Controlled-release systems
• Applicators
• Condom coatings
• Combination contraceptive products
• Manufacturing or purification methods
• Packaging systems
• Use of nonoxynol-9 with other contraceptive agents

These rights are generally product-specific rather than ingredient-wide. A formulation patent may protect a particular concentration range, polymer matrix, delivery vehicle, pH range, film-forming system, or release profile. It does not normally prevent another manufacturer from purchasing nonoxynol-9 and using it in a non-infringing product.

Patent strength of the nonoxynol-9 estate

The overall patent position is weak for the raw material and potentially moderate for selected delivery systems. The principal commercial barriers are more likely to be regulatory, manufacturing, distribution, and brand-related than composition-of-matter patents.

IP category	Likely strength
Nonoxynol-9 composition patent	Expired or commercially irrelevant
Generic surfactant use	Weak
Spermicide formulation	Variable
Vaginal film or controlled release	Potentially stronger
Applicator or delivery device	Product-specific
Manufacturing process	Moderate if impurity control is difficult
Brand and trade dress	Potentially important for retail products
Regulatory data exclusivity	Limited for an old active ingredient

Are there Paragraph IV challenges or Orange Book listings for nonoxynol-9?

Nonoxynol-9 does not have the type of dominant, branded prescription-drug Orange Book estate associated with high-value small-molecule products such as oncology or diabetes medicines.

The key points are:

• There is no widely recognized, active Orange Book patent estate covering nonoxynol-9 as a raw material.
• Paragraph IV litigation is not a central market feature for the ingredient.
• Any Paragraph IV dispute would normally concern a specific approved finished product, formulation, or delivery system.
• Over-the-counter monograph products generally do not generate the same patent-certification pattern as abbreviated new drug applications for prescription products.

Market-entry risk therefore depends more on whether a particular finished product is subject to an unexpired formulation or device patent than on the status of nonoxynol-9 itself.

Which companies supply nonoxynol-9?

Supply is fragmented across chemical manufacturers, specialty-chemical distributors, excipient vendors, and contract manufacturers. Supplier identity can vary by region, grade, and production route.

The procurement market typically evaluates:

• Ethoxylation consistency
• Average ethylene oxide number
• Free nonylphenol content
• Residual ethylene oxide
• Residual 1,4-dioxane
• Color and odor
• Hydroxyl value
• Acid value
• Water content
• Microbial quality
• GMP documentation
• Change-control procedures
• Supply continuity

Nonoxynol-9 is often sold under supplier-specific trade names or internal grades. A pharmaceutical buyer should not assume that a technical-grade nonylphenol ethoxylate is interchangeable with a pharmaceutical-grade material.

Manufacturing and supply-chain barriers

The chemistry is established, but pharmaceutical use requires tighter controls than industrial detergent applications. The main manufacturing issues are:

• Batch-to-batch distribution of ethoxylation levels
• Residual nonylphenol
• Residual ethylene oxide
• 1,4-dioxane formation
• Color and odor variation
• Oxidative degradation
• Trace metals and process contaminants
• Documentation of raw-material origin

Nonylphenol ethoxylates also face environmental scrutiny because some degradation products are persistent or endocrine-active. This creates substitution pressure in Europe and other jurisdictions with strict chemical-management policies.

How does nonoxynol-9 compare with other pharmaceutical surfactants?

Attribute	Nonoxynol-9	Polysorbate 80	Poloxamer 407	Polysorbate 20
Primary role	Spermicide and surfactant	Solubilizer and emulsifier	Solubilizer and stabilizer	Solubilizer and emulsifier
Mucosal-use profile	More constrained	Broad pharmaceutical use	Broad pharmaceutical use	Broad pharmaceutical use
New-drug adoption	Limited	Common	Common	Common
Environmental scrutiny	High	Moderate	Lower relative concern	Moderate
Commodity availability	High	High	High	High
Main risk	Irritation and chemical scrutiny	Peroxide and degradation impurities	Viscosity and gel behavior	Oxidation and impurities
Patent relevance	Low at ingredient level	Low at ingredient level	Low at ingredient level	Low at ingredient level

Nonoxynol-9 is more commercially defensible in established spermicide products than in new pharmaceutical development. A development team selecting it for a novel dosage form would face a higher regulatory burden than a team using a widely accepted compendial surfactant with a stronger pharmaceutical-use history.

What is the financial trajectory for nonoxynol-9?

The financial trajectory is best characterized as flat to declining in mature contraceptive markets and stable but specialized in excipient applications.

Revenue drivers

Positive drivers include:

• Low unit cost
• Established manufacturing technology
• Continued demand for low-cost spermicide
• Use in selected emerging markets
• Existing supplier qualification
• Compatibility with vaginal product platforms
• Potential demand from private-label products

Revenue pressures

Negative drivers include:

• Contraceptive substitution
• Low efficacy as a standalone method
• Mucosal-irritation concerns
• HIV and sexually transmitted infection labeling restrictions
• Environmental pressure on nonylphenol ethoxylates
• Formulator preference for polysorbates and poloxamers
• Limited new-product development
• Commodity pricing and supplier competition

The financial profile is therefore unlikely to resemble a high-margin specialty pharmaceutical ingredient. Pricing power is limited unless a supplier offers a validated pharmaceutical grade with strong impurity control, regulatory documentation, and reliable supply.

Scenario analysis

Scenario	Market outcome	Financial effect
Base case	Gradual contraction of spermicide demand; stable legacy excipient sales	Low single-digit decline or stagnation
Downside case	Accelerated substitution, environmental restrictions, supplier exits	Material volume decline and margin pressure
Upside case	Growth in low-cost nonhormonal contraception or new delivery systems	Modest volume recovery
Strategic case	Supplier differentiates through GMP grade and impurity control	Better margins without major volume growth

These are directional scenarios, not published market forecasts. No public financial statements support a precise standalone revenue projection.

What generic launch risks exist for nonoxynol-9 products?

Generic or private-label entry risk is high because:

• The active ingredient is old and widely available.
• Manufacturing technology is established.
• Raw-material switching is feasible after qualification.
• Composition-of-matter protection is absent.
• Retail consumers are familiar with low-cost contraceptive products.
• Contract manufacturers can produce several dosage forms.

The main barriers are product development and regulatory execution. A new entrant must establish acceptable performance for dissolution, sperm immobilization, content uniformity, microbiological quality, stability, packaging, and user administration.

For vaginal films, foams, and applicator-based products, device and formulation engineering can create greater entry barriers than the active ingredient itself.

What licensing deals and litigation affect nonoxynol-9?

Publicly disclosed licensing activity centered specifically on nonoxynol-9 is limited. Commercial arrangements are more likely to involve:

• Private-label manufacturing
• Brand licensing
• Distribution rights
• Contract development and manufacturing
• Applicator technology
• Vaginal-film platforms
• Retailer-exclusive products

There is no broadly recognized current patent litigation campaign controlling the nonoxynol-9 ingredient market. Litigation risk is more likely to arise from product liability, labeling, manufacturing quality, advertising claims, or device patents than from ingredient exclusivity.

Key Takeaways

• Nonoxynol-9 is an old, low-cost nonionic surfactant whose principal pharmaceutical use is as a vaginal spermicide.
• Its standalone market size and supplier revenue are not publicly disclosed in reliable audited datasets.
• Demand is mature to declining in developed contraceptive markets.
• The principal commercial risks are substitution, mucosal-irritation concerns, HIV-related labeling restrictions, and environmental scrutiny.
• Nonoxynol-9 has no meaningful active composition-of-matter patent barrier.
• Formulation, vaginal-film, applicator, packaging, and manufacturing patents may still affect individual products.
• Orange Book and Paragraph IV activity is limited compared with prescription small-molecule products.
• Excipient demand is more stable than spermicide demand but remains vulnerable to replacement by polysorbates, poloxamers, and newer surfactants.
• Supplier differentiation depends on pharmaceutical-grade documentation, impurity control, batch consistency, and supply reliability.
• The most likely financial outlook is stagnation or gradual decline, with limited upside from low-cost contraception and specialized delivery systems.

FAQs

Is nonoxynol-9 still approved as a contraceptive ingredient?

Yes. Nonoxynol-9 remains used in nonprescription vaginal contraceptive products in the United States, subject to applicable FDA requirements and labeling restrictions.

Does nonoxynol-9 prevent HIV or sexually transmitted infections?

No. Nonoxynol-9 is not an HIV or sexually transmitted infection preventive. Frequent use can increase mucosal irritation and may increase HIV transmission risk in high-risk populations (WHO & UNAIDS, 2002).

Is nonoxynol-9 a pharmaceutical excipient or an active ingredient?

It can be either. In spermicide products, it is the active contraceptive ingredient. In other formulations, it can function as a surfactant, emulsifier, wetting agent, or solubilizer.

Are nonoxynol-9 raw materials interchangeable between suppliers?

No. Different suppliers may produce materials with different ethoxylation distributions, free nonylphenol levels, residual 1,4-dioxane, color, odor, and performance. Pharmaceutical substitution requires qualification and regulatory change control.

Does nonoxynol-9 have a strong patent estate?

No. The ingredient itself is not protected by a meaningful current composition patent estate. Protection may exist for specific formulations, delivery systems, applicators, or manufacturing methods.

References

Centers for Disease Control and Prevention. (2024). Contraception and birth control methods. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (2023). Nonprescription drug products and vaginal contraceptive labeling requirements. U.S. Department of Health and Human Services.

World Health Organization, & Joint United Nations Programme on HIV/AIDS. (2002). WHO/CONRAD technical consultation on nonoxynol-9. World Health Organization.

World Health Organization. (2019). Family planning: A global handbook for providers. Johns Hopkins Center for Communication Programs and World Health Organization.